1. The role of Fas/FasL in immunosuppression induced by human tumors

   • Theresa L. Whiteside
   • Hannah Rabinowich

   REVIEW Pages: 175 - 184

2. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

   • R. Ridolfi
   • Emanuela Flamini
   • Dino Amadori

   ORIGINAL ARTICLE Pages: 185 - 193

3. Dexamethasone induces altered binding of regulatory factors to HLA class I enhancer sequence in MCF-7 breast tumour cell line

   • F. Rodriguez
   • Maximino Redondo
   • Francisco Ruiz-Cabello

   ORIGINAL ARTICLE Pages: 194 - 200

4. Anti-idiotype induction therapy: anti-CA125 antibodies (Ab₃) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab₁)

   • Birgit C. Schultes
   • Richard P. Baum
   • R. Madiyalakan

   ORIGINAL ARTICLE Pages: 201 - 212

5. The combination of interleukin-2 and interferon effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29

   • Sven Bungard
   • D. Flieger
   • Ulrich Spengler

   ORIGINAL ARTICLE Pages: 213 - 220

6. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells

   • Øystein Bruserud

   ORIGINAL ARTICLE Pages: 221 - 228

7. In vitro characterization of a recombinant ³²P-phosphorylated anti-(carcinoembryonic antigen) single-chain antibody

   • Mark R. Patrick
   • Kerry A. Chester
   • G. A. Pietersz

   ORIGINAL ARTICLE Pages: 229 - 237